Details of Disease

General Information of Disease (ID: DIS2YOWO)

Disease Name Myeloid neoplasm
Synonyms myeloid malignancy; myeloid neoplasm; myeloid tumour; myeloid tumor
Definition Proliferation of myeloid cells originating from a primitive stem cell.
Disease Hierarchy
DISCDP7W: Haematological malignancy
DIS2YOWO: Myeloid neoplasm
Disease Identifiers
MONDO ID
MONDO_0005170
UMLS CUI
C2939461
MedGen ID
445430
SNOMED CT ID
414792005

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 4 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
FGR TTPOGS1 Limited Biomarker [1]
ZFP36L1 TT8QVJO Limited Biomarker [2]
PDGFRA TT8FYO9 moderate Genetic Variation [3]
EGR1 TTE8LGD Strong Biomarker [4]
------------------------------------------------------------------------------------
This Disease Is Related to 16 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
BCORL1 OTPTFQN5 Limited Genetic Variation [5]
CCDC28A OTSWUMXT Limited Biomarker [6]
CCDC88C OTIU02BS Limited Biomarker [7]
DDX41 OT6KEIHP Limited Genetic Variation [8]
ETF1 OTH8C5U5 Limited Biomarker [2]
EVI2A OTR8RUXQ Limited Biomarker [9]
NUMA1 OTTKAVG4 Limited Genetic Variation [10]
PHF6 OT8DXI40 Limited Genetic Variation [5]
PIP4K2A OTO9JO9U Limited Biomarker [11]
PRR14L OT290EDE Limited Genetic Variation [12]
RAB8A OTPB54Y3 Limited Biomarker [13]
RPN2 OTJ1SKOA Limited Biomarker [14]
SMAD5 OTQNSVCQ Limited Biomarker [15]
TFAP2C OTUDIW05 Limited Biomarker [2]
ASXL1 OTX931AW Strong Biomarker [16]
FIP1L1 OTF91GTL Strong Genetic Variation [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DOT(s)

References

1 An unusual cytogenetic abnormality involving chromosomes 1 and 7 in a case of chronic myelomonocytic leukemia.Cancer Genet Cytogenet. 1995 Nov;85(1):75-7. doi: 10.1016/0165-4608(95)00139-5.
2 Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene.Cancer Genet Cytogenet. 2002 Apr 1;134(1):33-7. doi: 10.1016/s0165-4608(01)00605-7.
3 A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience.Am J Clin Pathol. 2018 Oct 1;150(5):421-431. doi: 10.1093/ajcp/aqy064.
4 Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.Blood. 2007 Jul 15;110(2):719-26. doi: 10.1182/blood-2007-01-068809. Epub 2007 Apr 9.
5 C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.Int J Hematol. 2018 Dec;108(6):652-657. doi: 10.1007/s12185-018-2514-3. Epub 2018 Aug 6.
6 Functional analysis of the NUP98-CCDC28A fusion protein.Haematologica. 2012 Mar;97(3):379-87. doi: 10.3324/haematol.2011.047969. Epub 2011 Nov 4.
7 A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFR responsive to combination treatment with imatinib mesylate and prednisolone.J Clin Pharm Ther. 2010 Dec;35(6):733-6. doi: 10.1111/j.1365-2710.2009.01130.x.
8 Myeloid neoplasms with germline DDX41 mutation.Int J Hematol. 2017 Aug;106(2):163-174. doi: 10.1007/s12185-017-2260-y. Epub 2017 May 25.
9 Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels.J Virol. 1995 Aug;69(8):5095-102. doi: 10.1128/JVI.69.8.5095-5102.1995.
10 Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.Cancer Genet. 2017 Apr;212-213:38-44. doi: 10.1016/j.cancergen.2017.03.004. Epub 2017 Mar 27.
11 A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival.Oncogene. 2015 Mar 5;34(10):1253-1262. doi: 10.1038/onc.2014.77. Epub 2014 Mar 31.
12 PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia.Leukemia. 2019 May;33(5):1184-1194. doi: 10.1038/s41375-018-0340-5. Epub 2018 Dec 20.
13 Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.Int J Hematol. 2019 Feb;109(2):197-205. doi: 10.1007/s12185-018-2562-8. Epub 2018 Nov 17.
14 A yeast artificial chromosome-based map of the region of chromosome 20 containing the diabetes-susceptibility gene, MODY1, and a myeloid leukemia related gene.Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3937-41. doi: 10.1073/pnas.93.9.3937.
15 Localization of SMAD5 and its evaluation as a candidate myeloid tumor suppressor.Cancer Res. 1997 Sep 1;57(17):3779-83.
16 Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.J Clin Invest. 2018 Dec 3;128(12):5383-5398. doi: 10.1172/JCI121366. Epub 2018 Oct 29.
17 Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.Cancer Genet. 2018 Jan;220:13-18. doi: 10.1016/j.cancergen.2017.10.004. Epub 2017 Oct 23.